Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Cash & Current Investments (2020 - 2025)

Rapid Micro Biosystems' Cash & Current Investments history spans 6 years, with the latest figure at $18.4 million for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 46.02% to $18.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.4 million, a 46.02% decrease, with the full-year FY2025 number at $18.4 million, down 46.02% from a year prior.
  • Cash & Current Investments hit $18.4 million in Q4 2025 for Rapid Micro Biosystems, down from $41.2 million in the prior quarter.
  • Over the last five years, Cash & Current Investments for RPID hit a ceiling of $221.0 million in Q3 2021 and a floor of $18.4 million in Q4 2025.
  • Historically, Cash & Current Investments has averaged $83.5 million across 5 years, with a median of $67.9 million in 2023.
  • Biggest five-year swings in Cash & Current Investments: soared 329.26% in 2021 and later plummeted 59.61% in 2022.
  • Tracing RPID's Cash & Current Investments over 5 years: stood at $193.5 million in 2021, then plummeted by 43.85% to $108.6 million in 2022, then plummeted by 37.53% to $67.9 million in 2023, then tumbled by 49.87% to $34.0 million in 2024, then crashed by 46.02% to $18.4 million in 2025.
  • Business Quant data shows Cash & Current Investments for RPID at $18.4 million in Q4 2025, $41.2 million in Q3 2025, and $31.3 million in Q2 2025.